📊 ACAD Key Takeaways
Is Acadia Pharmaceuticals Inc. (ACAD) a Good Investment?
Acadia shows troubling operational fundamentals with abnormally inflated gross margins (255.5%), negative operating income, and essentially flat profitability despite 11.9% revenue growth. While strong liquidity and positive free cash flow provide a buffer, the company's minimal returns (ROE 0.3%, ROA 0.2%) and deteriorating operating efficiency suggest structural profitability challenges that require resolution.
ACADIA shows solid core fundamentals with double-digit revenue growth, strong gross margins, positive operating income, and an exceptionally strong balance sheet with no leverage. However, earnings quality looks mixed because net income is far above operating income while free cash flow remains modest relative to reported profits, suggesting some benefit may be non-operational or less cash-backed. The company appears financially healthy, but the durability of profit expansion needs confirmation in future filings.
Acadia Pharmaceuticals Inc. Key Strengths (ACAD)
- Strong liquidity with 3.59x current ratio and $282.2M cash providing financial flexibility
- Positive revenue growth of 11.9% YoY demonstrates market demand for products
- Zero long-term debt and positive free cash flow of $28.8M support operational runway
- Revenue grew 11.9% year over year while remaining profitable at the operating level
- Balance sheet is strong with $177.69M in cash, no meaningful long-term debt, and high liquidity ratios
- Gross margin of 63.9% and positive free cash flow indicate a scalable and cash-generating core business
ACAD Stock Risks: Acadia Pharmaceuticals Inc. Investment Risks
- Abnormally elevated gross margin (255.5%) indicates significant accounting anomalies or operational issues requiring explanation
- Negative operating income (-$4.6M) and extremely poor returns (ROE 0.3%, ROA 0.2%) signal fundamental unprofitability despite revenue growth
- Profitability stagnation with net income flat YoY despite 11.9% revenue growth indicates deteriorating operational efficiency and execution
- Net income of $391.00M appears unusually high relative to $104.81M of operating income, raising earnings quality concerns
- Free cash flow margin of 9.8% is much lower than net margin of 36.5%, suggesting profit conversion to cash is limited
- As a pharmaceutical company, growth and margins may be vulnerable to product concentration, competition, and regulatory execution
Key Metrics to Watch
- Gross margin normalization toward industry standards and root cause of margin anomaly
- Operating income recovery and path to sustainable positive operating margin
- Free cash flow trend relative to working capital changes and capital allocation efficiency
- Operating cash flow and free cash flow conversion relative to net income
- Revenue growth and operating margin sustainability
Acadia Pharmaceuticals Inc. (ACAD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.59x current ratio provides a solid financial cushion.
ACAD Profit Margin, ROE & Profitability Analysis
ACAD vs Healthcare Sector: How Acadia Pharmaceuticals Inc. Compares
How Acadia Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acadia Pharmaceuticals Inc. Stock Overvalued? ACAD Valuation Analysis 2026
Based on fundamental analysis, Acadia Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acadia Pharmaceuticals Inc. Balance Sheet: ACAD Debt, Cash & Liquidity
ACAD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acadia Pharmaceuticals Inc.'s revenue has grown significantly by 121% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.37 indicates the company is currently unprofitable.
ACAD Revenue Growth, EPS Growth & YoY Performance
ACAD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $244.3M | $3.6M | $0.02 |
| Q3 2025 | $250.4M | $32.8M | $0.20 |
| Q2 2025 | $242.0M | $26.7M | $0.16 |
| Q1 2025 | $205.8M | $16.6M | $0.10 |
| Q3 2024 | $211.7M | $32.8M | $0.20 |
| Q2 2024 | $165.2M | $1.1M | $0.01 |
| Q1 2024 | $118.5M | $16.6M | $0.10 |
| Q3 2023 | $130.7M | -$27.2M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Acadia Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ACAD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acadia Pharmaceuticals Inc. (CIK: 0001070494)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 2, 2026 | 4 | xslF345X06/ownership.xml | View → |
| Jun 1, 2026 | 4 | xslF345X06/form4-06012026_060612.xml | View → |
| Jun 1, 2026 | 4 | xslF345X06/form4-06012026_060610.xml | View → |
| Jun 1, 2026 | 4 | xslF345X06/form4-06012026_060608.xml | View → |
| Jun 1, 2026 | 4 | xslF345X06/form4-06012026_060606.xml | View → |
❓ Frequently Asked Questions about ACAD
What is the AI rating for ACAD?
Acadia Pharmaceuticals Inc. (ACAD) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACAD's key strengths?
Claude: Strong liquidity with 3.59x current ratio and $282.2M cash providing financial flexibility. Positive revenue growth of 11.9% YoY demonstrates market demand for products. ChatGPT: Revenue grew 11.9% year over year while remaining profitable at the operating level. Balance sheet is strong with $177.69M in cash, no meaningful long-term debt, and high liquidity ratios.
What are the risks of investing in ACAD?
Claude: Abnormally elevated gross margin (255.5%) indicates significant accounting anomalies or operational issues requiring explanation. Negative operating income (-$4.6M) and extremely poor returns (ROE 0.3%, ROA 0.2%) signal fundamental unprofitability despite revenue growth. ChatGPT: Net income of $391.00M appears unusually high relative to $104.81M of operating income, raising earnings quality concerns. Free cash flow margin of 9.8% is much lower than net margin of 36.5%, suggesting profit conversion to cash is limited.
What is ACAD's revenue and growth?
Acadia Pharmaceuticals Inc. reported revenue of $268.1M.
Does ACAD pay dividends?
Acadia Pharmaceuticals Inc. does not currently pay dividends.
Where can I find ACAD SEC filings?
Official SEC filings for Acadia Pharmaceuticals Inc. (CIK: 0001070494) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACAD's EPS?
Acadia Pharmaceuticals Inc. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACAD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Acadia Pharmaceuticals Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACAD stock overvalued or undervalued?
Valuation metrics for ACAD: ROE of 0.3% (sector avg: 15%), net margin of 1.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACAD's AI grade for 2026?
Our dual AI analysis gives Acadia Pharmaceuticals Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACAD's free cash flow?
Acadia Pharmaceuticals Inc.'s operating cash flow is $34.0M, with capital expenditures of $5.2M. FCF margin is 10.7%.
How does ACAD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.4% (avg: 12%), ROE 0.3% (avg: 15%), current ratio 3.59 (avg: 2).